To date, scientific research has often focused on one sex, with assumptions that study of the other sex would yield similar results. However, many diseases affect males and females differently. The sex of a patient can affect the risk for both disease susceptibility and progression. Such differences can be brought to the laboratory bench to be investigated, potentially bringing new treatments back to the clinic. This method of research, known as a "bedside to bench to bedside" approach, has been applied to studying sex differences in multiple sclerosis (MS). Females have greater susceptibly to MS, while males have worse disease progression. These two characteristics of the disease are influenced by the immune system and the nervous system, respectively. Thus, sex differences in each system must be studied. Personalized medicine has been at the forefront of research recently, and studying sex differences in disease fits with this initiative. This review will discuss the known sex differences in MS and highlight how investigating them can lead to new insights and potential treatments for both men and women. V C 2016 Wiley Periodicals, Inc.
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THE IMPORTANCE OF STUDYING BOTH SEXES; AN OVERVIEW OF SEX DIFFERENCES IN NEUROLOGICAL DISEASES
Understanding mechanisms underlying sex differences in disease can lead to the discovery of natural disease modifiers. It is important to study both sexes for many reasons. The sex of a patient often changes the risk for disease susceptibility or progression. In addition, optimal dosing of treatments, considering efficacy and side effects, can differ between the two sexes. Optimizing the dose for one sex and assuming that findings are no different in the other sex is underserving a large portion of patients. The risk to benefit ratio for a given dose must be determined for each of the two sexes. Finally, the study of both sexes may lead to the discovery of unexpected natural disease modifiers.
Researchers studying the multiple sclerosis (MS) model, experimental autoimmune encephalomyelitis (EAE), found that female mice, rats, rabbits, and guinea pigs exhibited protection from disease when they were pregnant (Abramsky, 1994; Langer-Gould et al., 2002) . Such an observation would never have been made if only the male population were studied. Since it had been anecdotally observed that there were protective effects for women with MS when they were pregnant, this observation in animals suggested that the improvement of disease in pregnant women with MS was due to an important biological disease modifier of pregnancy, not merely an SIGNIFICANCE Understanding sex differences in disease is critical to proper treatment of both male and female patients. Clinical observations of patients with multiple sclerosis (MS) entail increased susceptibility in women, while men have worse disease progression. Taking these observations to the laboratory bench has allowed researchers to disentangle mechanisms underlying sex differences and to investigate therapeutics based on these insights. Studying sex differences in other autoimmune and neurodegenerative diseases in the same "bedside to bench to bedside" manner may uncover novel therapeutics.
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When researchers included both females and males in adoptive transfer EAE experiments, they found that females, as compared with males, were more susceptible to disease in the relapsing-remitting model . Since epidemiologic studies showed that men were less susceptible to MS than women, these preclinical studies again supported a biologic mechanism for the sex difference in MS, not mere differences in MS reporting or perception of symptoms in women compared to men.
MS: AN AUTOIMMUNE DISEASE OF THE
CENTRAL NERVOUS SYSTEM MS is a complex disease involving both the immune system and the central nervous system (CNS). In MS, T lymphocytes are activated and migrate through the blood-brain barrier. These T-cells release cytokines that activate microglia and astrocytes, as well as recruit macrophages and other lymphocytes, leading to demyelination and irreversible neurodegeneration (Brosnan and Raine, 1996) . There are several different types of MS. Relapsing-remitting MS (RRMS) is characterized by episodes of autoimmune infiltration inducing a new symptom or significantly worsening a preexisting symptom, each known as a relapse. Relapses are followed by a period of autoimmune quiescence and clinical stability, or remission. Over decades, RRMS often transitions into secondary progressive MS (SPMS). Patients with MS who no longer exhibit relapses and remissions but, instead, slowly accumulate worse neurodegeneration, have SPMS. Approximately 10% of patients with MS do not have an initial relapsing phase that precedes the neurodegenerative phase, and this is termed primary progressive MS (PPMS) MS exhibits sex differences in both the immune response and neurodegeneration, affecting disease susceptibility and progression, respectively. However, sex differences in the immune system appear to be different from sex differences in the CNS; women are more susceptible to MS (Whitacre et al., 1999) , but men are more likely to have disease progression (Tomassini and Pozzilli, 2009; Koch et al., 2010; Shirani et al., 2012) . This poses the question, if the incidence of disease is higher, and peripheral immune responses are more robust in women, then why isn't disability progression faster in women? If anything, there is faster progression in men. We have hypothesized that sex-related factors could play different roles in the immune system vs. the CNS, and thus different roles in susceptibility vs. disability progression .
SEX DIFFERENCES IN MS SUSCEPTIBILITY (FEMALE > MALE) Disease Onset
There is a distinct female preponderance to a variety of autoimmune diseases including MS, systemic lupus erythematosus, and rheumatoid arthritis (Whitacre et al., 1999) . Consistent with increased susceptibility in females are reports that immune responses are more robust in healthy females compared with males, including autoantigen-specific responses in MS (Pelfrey et al., 2002; Kantarci et al., 2008; Moldovan et al., 2008; Libert et al., 2010) . The female-to-male ratio in MS varies somewhat by geographic region from 2:1 to 3:1, and has increased in the past decades, with a few notable exceptions (KochHenriksen and Sorensen, 2010) . This increase in the female-to-male ratio is driven by increased incidence in women, not by decreased incidence in men. The reasons for the increased incidence in women remain speculative. However, the short time span over which it is occurring excludes a purely genetic cause (Orton et al., 2006) . Instead, it has been proposed to be due to gene-environment interactions or epigenetic factors (Greer and McCombe, 2011; Voskuhl and Gold, 2012) .
RRMS
While the female preponderance for RRMS has been established for many years (Runmarker and Andersen, 1993 ), a recent study demonstrated a 17.7% higher relapse rate in females compared with males who have RRMS throughout the entire duration of disease and at any age (Kalincik et al., 2013) . Also, patients with RRMS have a greater female-to-male ratio when they have at least four relapses per year in the first 5 years of disease (3.3:1) than patients who experience no relapses in the first 5 years (2.3:1) (Kalincik et al., 2013) . Females also have a higher cumulative hazard risk of relapses than males 40 years after disease onset (Kalincik et al., 2013) . Conversely, there is no distinct sex difference in patients with PPMS (1.2:1), the type of MS without relapses (Kalincik et al., 2013) .
Preclinical Model for RRMS
EAE in the SJL strain of mouse exhibits a relapsingremitting pattern (Brown et al., 1982) . Therefore, this model has been used extensively to study immunological mechanisms of relapses in MS by focusing on myelinspecific immune responses in the lymph nodes and spleen, inflammation and demyelination in the spinal cord, and clinical EAE scores that principally reflect walking disability. Females compared with males are more susceptible to EAE in the SJL strain .
SEX DIFFERENCES IN MS DISABILITY PROGRESSION (MALE > FEMALE) Disease Progression in Patients with RRMS
For years it was reported that early predictors of future permanent disability in MS included male sex, age of onset, and degree of recovery from the first episode (Runmarker et al., 1994) . A large natural history study of all MS subtypes showed that the median time between disease onset and reaching a given disability level was shorter in men (Confavreux et al., 2003) . Other studies also showed that being male was associated with shorter time to disability progression in RRMS (Weinshenker et al., 1991; Weinshenker, 1994; Savettieri et al., 2004) . These publications addressing changes in long-term disability progression were in contrast to findings of no sex difference in disability progression during short-term trials testing anti-inflammatory treatments for effects on relapses. A natural history study of untreated patients with MS found that male sex was associated with a shorter time to, and a younger age for, conversion to SPMS (Koch et al., 2010) . Another study showed that males have a more severe disease phenotype with faster accumulation of disability (Tomassini and Pozzilli, 2009) , with yet another showing that male sex and older age at onset were predictive of more rapid progression from disease onset of RRMS (Shirani et al., 2012) . Finally, a very large registry-based study of over 14,000 patients revealed that male relapse-onset progressive patients accumulated disability faster than female relapse-onset progressive patients (Ribbons et al., 2015) .
While the above summarizes sex differences in several MS disabilities as measured by composites, cognition is a specific disability that appears to be worse in men. An early study showed that male patients with MS performed worse on several cognitive subtests compared with female patients with MS who were matched for age, education, and other neurologic and emotional measures (Beatty and Aupperle, 2002) . Later, a large cohort of subjects with MS (n 5 533) were categorized as cognitively normal or impaired based on their performance on a battery of neuropsychological tests. These subjects also underwent genotyping for the apolipoprotein E (APOE) allele polymorphisms. Cognitive decline was more prominent in men and was associated with the presence of the epsilon4 allele (Savettieri et al., 2004) . To investigate the relationship between subcortical gray matter atrophy and cognition in early relapse-onset MS, structural magnetic resonance imaging (MRI) and neuropsychological testing were performed in 80 women with MS and 40 men with MS, as well as in 30 healthy women and 20 healthy men. Several deep gray matter structures showed volume loss in MS compared with healthy controls, with larger effects in men with MS (211%) than in women with MS (26.3%). Also, more cognitive domains were affected in men than in women (Schoonheim et al., 2012) . Among the subcortical gray matter structures assessed, it was thalamic atrophy which showed the closest association with cognitive impairment. Studies of other substructures, such as cortical gray matter atrophy, are needed.
PPMS
It has long been known that the characteristic profile of PPMS is being male, being older, and having spinal cord lesions (Thompson, 2004) . A recent study aimed to identify predictors to develop PPMS in a population of subjects with radiologically isolated syndrome (RIS). RIS is the term used to describe the presence of white matter lesions not associated with other clinical symptoms (Granberg et al., 2013) . It was found that male sex, older age, and lesions predominantly in the spinal cord were the three predictors of evolution from RIS to PPMS (Kantarci et al., 2016) . However, during the primary progressive disease course, males do not have significantly faster disease accumulation than women, contrary to their faster disease accumulation in the RRMS disease course (Ribbons et al., 2015) .
Preclinical Model for Neurodegeneration
As stated above, EAE has historically been used to study immune responses, walking disability, and spinal cord pathology. However, over the past decade, EAE has been shown to also include neurodegenerative pathology beyond the spinal cord, particularly in the chronic EAE model in the C57BL/6 strain. The cerebellum has white matter inflammation, demyelination, and axonal loss as well as Purkinje cell loss (MacKenzie-Graham et al., 2009; Du et al., 2014) . The hippocampus is also affected during EAE, displaying CA1 atrophy and loss of synaptic integrity, the latter of which correlated with altered functional synaptic transmission using electrophysiology of hippocampal slices (Ziehn et al., 2010 (Ziehn et al., , 2012b Nistico et al., 2013) . Cerebral cortical structures in EAE show synaptic loss, transected axons, and loss of callosal projecting neurons and pyramidal neurons (Rasmussen et al., 2007; Du et al., 2014; Spence et al., 2014) , while the corpus callosum has areas of demyelination, with decreased axon conduction by electrophysiology (Rasmussen et al., 2007; Crawford et al., 2010) . Additionally, the striatum is affected by altered excitatory transmission, again associated with loss of synapses and dendritic spines (Centonze et al., 2009 ). Studies of optic neuritis also use EAE to show loss of retinal ganglion cell bodies and optic nerve axons. In addition to pathological abnormalities in EAE brain tissue, whole brain atrophy (MacKenzie-Graham, 2012; Lepore, Waiczies et al., 2013; Spence et al., 2014) and gray matter atrophy in the cerebellum and cortex have been seen in EAE by MRI (MacKenzie-Graham et al., 2006 . T2 lesion hyperintensities in the brainstem and cerebellum of EAE have also been shown. (MacKenzie-Graham et al., 2006 Waiczies et al., 2012) .
UNRAVELING MECHANISMS UNDERLYING SEX DIFFERENCES IN DISEASE Bedside to Bench to Bedside Approach
Sex differences in disease are widespread. Many of these differences were first observed at the clinical bedside, and then brought to the laboratory bench to be mechanistically dissected. These findings can then lead to novel treatments for clinical trials. This is a "bedside to bench to bedside" approach . Using this approach, sex differences in disease can serve as clinical observations that provide a foundation known to be physiologically relevant in humans, as opposed to starting with a molecule of interest in preclinical models without known physiological relevance. The "bedside to bench to bedside" approach in drug development is a conceptual shift, since usually the molecule comes first, with questions of physiologic relevance coming second.
Sex Hormones and Sex Chromosomes in Sex Differences
Sex differences in any disease may be due to sex hormones, sex chromosomes, or both since a role for one is not mutually exclusive of a role for the other (Voskuhl, 2011) . Regarding sex hormones, physiologic levels of cycling estradiol and progesterone could play a role in females. Likewise, physiologic levels of testosterone in males could play a role. Regarding sex chromosomes, the XX sex chromosome complement could play a role in females or the XY complement in males. Sophisticated approaches can now discern between these possibilities.
THE ROLE OF SEX HORMONES IN SEX DIFFERENCES IN MS Testosterone
Clinical Observations. As previously stated, men have demonstrated worse disease progression compared with females (Runmarker et al., 1994; Weinshenker, 1994; Confavreux et al., 2003; Savettieri et al., 2004; Tomassini and Pozzilli, 2009; Koch et al., 2010; Shirani et al., 2012; Ribbons et al., 2015) . This is likely due to factors other than testosterone since clinical data from converging lines of evidence from independent sources suggest that testosterone is protective in men with MS. A retrospective cohort study was conducted using analysis of English National Hospital records from 1999 to 2011. It found that men with testicular hypofunction, a proxy for low testosterone levels, were at increased risk to develop MS, suggesting an immunosuppressive role of testosterone (Pakpoor et al., 2014a,b) . In line with these results, patient reports show that men with MS have relatively low testosterone levels compared with healthy men (Wei and Lightman, 1997; Foster et al., 2003; Bove et al., 2014) . Among men with MS, those with lower testosterone levels had worse Expanded Disability Status Scale (EDSS) scores, and when followed longitudinally, those with lower testosterone levels showed more decline on longitudinal cognitive testing (as assessed by the Symbol Digit Modalities Test (SDMT)) (Bove et al., 2014) . These results suggest possible neuroprotective effects of higher levels of endogenous testosterone. While it is possible that low testosterone levels are an effect of disease, the study reporting testicular hypofunction in patients prior to their development of MS suggested that low testosterone in men with MS was not merely a consequence of disease (Pakpoor et al., 2014b) .
Preclinical Studies. Preclinical data have revealed a protective effect of testosterone in two different MS models, EAE (Dalal et al., 1997; Bebo et al., 1999; Maccio et al., 2005) and cuprizone diet (Hussain et al., 2013; Patel et al., 2013) . In EAE, testosterone treatment decreased EAE scores of walking disability, reduced inflammation and demyelination, and spared axons (Dalal et al., 1997; Bebo et al., 1999; . As reviewed above, in addition to walking disability, EAE in C57BL/6 mice involved cognitive dysfunction. Testosterone treatment has been shown to be protective when assessing cognitive outcomes during EAE. Specifically, testosterone treatment induced an increase in synapses by neuropathology and improved synaptic transmission by electrophysiology (Ziehn et al., 2012b) . Synaptic stripping and loss is observed in MS cortex (Trapp et al., 2007; Dutta et al., 2011; Spence et al., 2014) , and testosterone treatment in cognitive neurodegenerative models improves structure and function of dendrites and synapses in the cerebral cortex (Ziehn et al., 2012b) . Together, these reports suggest a mechanistic hypothesis whereby testosterone treatment in MS may increase synapses and their function in cortical gray matter. Effects of testosterone treatment may be mediated through direct binding of testosterone to the androgen receptor. Alternatively, testosterone can be converted to estrogen in the brain by aromatase to mediate neuroprotection Saldanha et al., 2011; Rensel et al., 2013) . This hypothesis is consistent with the ability of estrogen treatment to increase dendritic spines, synapses, and cognitive function in preclinical models of cognitive decline (Yankova et al., 2001; Waters et al., 2009; Smejkalova and Woolley, 2010; Inagaki et al., 2012; Ziehn et al., 2012a; Kramar et al., 2013) . Beneficial effects on synapses are not mutually exclusive of additional potential effects of testosterone treatment in MS on remyelination of white matter (Hussain et al., 2013) or immunomodulation (Bebo et al., 1999; Liva and Voskuhl, 2001; . Indeed, many complementary pathways may ultimately be involved in testosterone-mediated neuroprotection.
Testosterone-mediated neuroprotection has also been shown in other preclinical cognitive neurodegenerative models including mild cognitive impairment, Alzheimer disease, and ApoE-related cognitive impairment (Raber et al., 2002; McAllister et al., 2010; Rosario et al., 2010 Rosario et al., , 2012 Li et al., 2013; Kang et al., 2014) .
Clinical Trials. A single-arm crossover pilot clinical trial of testosterone treatment in men with MS revealed beneficial effects of treatment on brain atrophy, muscle mass, and immune markers. Ten men with RRMS participated in an open-label Phase 2 trial. Subjects were observed prior to treatment for 6 months, followed by testosterone treatment for another 12 months. This treatment increased serum testosterone levels from the low-normal to high-normal range (Sicotte et al., 2007) . Brain MRIs were obtained every month. Compared with the pretreatment phase, there was slowing in the rate of whole brain atrophy by 67% during testosterone treatment (Sicotte et al., 2007) . Whole brain atrophy in MS is driven by gray matter atrophy, and gray matter atrophy has been used as a biomarker for permanent disability (Pirko et al., 2007; Fisniku et al., 2008; Rudick et al., 2009; Arnold and De Stefano, 2013; Hofstetter et al., 2014; Lavorgna et al., 2014; Sormani et al., 2014) . Thus, further analysis of the same MRIs by other investigators focused on gray matter. It was found that testosterone treatment significantly reduced gray matter atrophy compared with pretreatment . Peripheral blood mononuclear cell (PBMC) analyses revealed modest immunomodulatory properties with interesting increases in neurotrophic growth factor production during testosterone treatment (Gold et al., 2008) . Cognition was also improved with testosterone treatment as seen by increased Paced Auditory Serial Addition Test (PASAT) scores as well as increased spatial memory (Sicotte et al., 2007) . However, this was likely confounded by a practice effect of repeated testing.
While any one of these observations in isolation could be considered merely suggestive, consideration of all supports the hypothesis that testosterone supplementation in men with MS, boosting them from the lownormal range to the high-normal range, may be protective (Sicotte et al., 2007; Gold et al., 2008; Kurth et al., 2014) . Thus, a larger Phase 2, multicenter, placebocontrolled trial of testosterone is now warranted in men with MS.
Estradiol and Progesterone
Clinical Observations. The onset of puberty correlates with an increased onset of disease in women, but not men (Ramagopalan et al., 2009 ). An MRI study of patients with RRMS revealed an increase in number and volume of enhancing lesions during the week leading up to the first day of the menstrual period (Pozzilli et al., 1999) . However, no increase in clinical relapses has been noted during menopause or in low estrogen times in the menstrual cycle. A study on the effects of oral contraceptives on disease incidence in women showed no significant relationship (Hernan et al., 2000) . These studies suggest that physiological cycling levels of estradiol and progesterone have unclear effects on disease onset and relapses in patients with RRMS.
Circulating levels of ovarian hormones during a woman's menstrual cycle have correlated with changes in preexisting symptoms prior to the menstrual period, a time when estradiol and progesterone levels are low (Smith and Studd, 1992; Zorgdrager and De Keyser, 1997) . Patients using oral contraceptives, containing both estrogen and progesterone, no longer had worsening of symptoms during the premenstrual period (Zorgdrager and De Keyser, 1997) . Additionally, near 50% of postmenopausal women reported a worsening of symptoms (Smith and Studd, 1992) . Postmenopausal women who were taking hormone replacement therapies reported an improvement in their symptoms (Smith and Studd, 1992) . Notably, along with biological changes, many women undergo social and environmental changes once they are postmenopausal, which complicates direct correlations with hormones in observational studies (Bove, 2016) . One report showed that patients who started using oral contraceptives after disease onset experienced a milder disease course compared with those who used oral contraceptives before disease onset or never used them (Sena et al., 2012) . In another study, women with RRMS who used oral contraceptives were less likely to develop SPMS (Gava et al., 2014) . However, a different study showed that those who used oral contraceptives had a higher risk of reaching an EDSS score of 6 (D 'Hooghe et al., 2012) . Overall, the effects of physiological levels of circulating ovarian hormones on MS symptoms and disability progression remain unclear.
Preclinical Studies. Preclinical studies of ovariectomized (OVX) rodent MS models have studied the effects of adult sex hormones on disease. The results from several studies leave the effects of ovarian hormones on EAE disease course controversial. Some studies have shown earlier onset and worse clinical disease in OVX mice compared with sham controls Lelu et al., 2010) , while another group reported no difference in EAE disease course between OVX and sham controls (Voskuhl and Palaszynski, 2001) . One study in rats also showed worse disease in OVX females (Hoffman et al., 2001) .
Ovarian hormone treatments in EAE showed that treatment with estradiol ameliorated EAE clinical disease severity in both intact and OVX animals (Trooster et al., 1993; Bebo et al., 2001; Ito et al., 2001; Matejuk et al., 2001) . A dose response was shown for estradiol whereby higher doses were more protective . Pregnancy levels of estrogens were clearly protective, while lower levels were modest. Progesterone alone has been shown to have only mild effects on EAE clinical disease in C57BL/6 mice. Progesterone treatment decreased EAE clinical disease severity and decreased demyelinating lesions in the spinal cord (Garay et al., 2007 (Garay et al., , 2008 (Garay et al., , 2009 ). However, when progesterone treatment was administered to SJL female mice, no significant effects on EAE were observed (Kim et al., 1999) . Ovarian hormone treatment in rats resulted in slight alleviation of disease with estradiol treatment, and worsening of disease with progesterone treatment alone (Hoffman et al., 2001 ). However, combined treatment with estradiol and progesterone had greater amelioration of disease than estradiol alone (Hoffman et al., 2001; Garay et al., 2008) .
Clinical Trials. The effects of oral contraceptives were studied prospectively in a clinical trial. The study used the standard of care, interferon beta, in combination with either low or high doses of ethinyl estradiol in combination with the progestin desogestrel in a 96-week trial. Significant decreases in the cumulative number of combined unique active lesions and Gd-enhancing lesions were seen in patients receiving the high dose; however, this was not the primary outcome measure. No other MRI outcomes displayed significant results. No difference on relapse rate, the primary outcome, was observed (Pozzilli et al., 2015) . Further trials of high-dose estradiol containing oral contraceptives in MS are lacking. Increased risk of breast cancer must be considered in such trials because estradiol binds strongly to estrogen receptor (ER) alpha, the mediator of adverse events with oral contraceptives and hormone replacement therapy (Schairer et al., 2000) .
The Protective Effects of Pregnancy in Females with RRMS
Clinical Observations. Disease is ameliorated during late pregnancy in both MS and the MS model EAE (Abramsky, 1994; Confavreux et al., 1998) . A landmark study showed that there was over 70% reduction in MS relapses during the third trimester of pregnancy (Confavreux et al., 1998) . Several groups then began investigating which biological factor of late pregnancy might mediate this protection from relapses at the laboratory bench. Many hormones are increased during late pregnancy, including estriol, estradiol, and progesterone, that could contribute to the protective effects of pregnancy on MS. Estriol is unique to pregnancy in that estriol levels are absent in women during nonpregnancy but are made by the fetal placental unit and reach high levels during the third trimester, the time when a 70% decrease in relapse rate was reported (Confavreux et al., 1998) . Estriol was therefore studied for its protective role during EAE in preclinical studies. Estriol is also known to be the safest of the estrogens (Takahashi et al., 2000; Granberg et al., 2002) . ERa has been implicated in promoting breast cancer, while ERb has been shown to be less toxic, potentially inhibiting breast cancer (Paruthiyil et al., 2004) . Estriol binds ERb with higher affinity than ERa (Kuiper et al., 1997) .
Preclinical Studies. Investigation of the effects of estriol treatment in the EAE model showed amelioration of disease severity compared with those treated with placebo when treatment was given either before or after disease induction and in several EAE models (Jansson et al., 1994; Kim et al., 1999; Bebo et al., 2001) . Pathology revealed less inflammation, less demyelination, and sparing of axons in the spinal cord in estriol-treated animals compared with placebo (Kim et al., 1999) . Estriol treatment also resulted in sparing of hippocampal CA1 volume along with preservation of synapses and reduced microglial activation (Ziehn et al., 2012a) . This could be due to estriol acting on either ERa or ERb, since both have been implicated in estrogen's protective effects in EAE (Enmark and Gustafsson, 1999; Liu et al., 2003; Polanczyk et al., 2003) . ERa-mediated protection affects all stages of disease, while ERb-mediated protection affects the chronic stage of the disease (Tiwari-Woodruff et al., 2007) . This is consistent with reports of ERb being expressed widely in the brain (Enmark and Gustafsson, 1999) , potentially acting though microglia, oligodendrocytes, or dendritic cells (Du et al., 2011; Saijo et al., 2011; Khalaj et al., 2013; Wu et al., 2013) . Protection against disease was also seen in males treated with estriol, not only females . As described above, therapeutic effects of estradiol and progesterone were also investigated since they too could contribute to disease improvement in late pregnancy (see above).
Pregnancy is protective for T helper 1 (Th1)-, not Th2-, mediated immune diseases, due to pregnancy skewing the immune response to Th2 so as not to reject the fetus (Marzi et al., 1996) . Therefore, estriol may be beneficial for other Th1-mediated immune diseases such as psoriasis and rheumatoid arthritis.
Clinical Trials. Since estriol was protective in EAE, clinical trials in women with MS began. A small pilot Phase 2a trial showed a 70% to 80% reduction in inflammatory lesions in white matter on brain MRI (Sicotte et al., 2002) , and PBMCs showed favorable immunomodulation (Soldan et al., 2003) . A larger Phase 2b, randomized, placebo-controlled trial of estriol vs. placebo was conducted in women with RRMS taking standard-of-care MS treatment (glatiramer acetate). The study hit its primary outcome measure of relapse reduction. Specifically, when these patients were given estriol in addition to the standard of care, there was a one-half to one-third further reduction in annualized relapse rates over and above that provided by standard-of-care treatment (Voskuhl et al., 2016) . Promising effects on exploratory outcomes showed improved cognition and decreased fatigue, with slowing of cortical gray matter atrophy on brain MRI (Voskuhl et al., 2016) . A Phase 3 trial is needed to confirm the benefit of estriol treatment in women with RRMS.
The other potential hormone of pregnancy could be progesterone. There is a remarkable increase in relapse rate postpartum, when progesterone and estrogen levels decrease dramatically (Confavreux et al., 1998) . A French group followed up on this observation with a clinical trial treating postpartum women with progesterone, aiming to decrease relapse rate as the primary outcome. The results from this study have not been published to date, but the study was terminated when it became clear that it would not hit its primary outcome (ClinicalTrials.gov identifier: NCT00127075).
While a protective role of estriol in MS is not mutually exclusive of other pregnancy factors also playing a role, 20 years after the observation of the decreased relapses in women with MS during the third trimester, no pregnancy factor other than estriol has shown efficacy in a Phase 2 trial. Thus, other autoimmune diseases known to improve during pregnancy, such as psoriasis and rheumatoid arthritis (Whitacre et al., 1999) , should also be investigated for a protective effect of estriol at a dose recapitulating a pregnancy level.
THE ROLE OF SEX CHROMOSOMES IN ESTABLISHING SEXUAL DIMORPHISMS IN
MS As described above, there have been extensive studies investigating the role of sex hormones in MS, but this is not exclusive of an additional role of sex chromosomes. Sex chromosome differences are inherently tied to sex hormone differences because the XY genotype is associated with testes and the XX genotype is associated with ovaries. Elegant studies have established how to determine the effect of sex chromosome complement separate from effects of gonadal type and sex hormones (Smith-Bouvier et al., 2008) , using the "four core genotype" (FCG) mice (Arnold and Chen, 2009 ). Specifically, the sex determining region of the Y (Sry) gene on the Y chromosome that encodes for testicular development has been deleted; these mice are signified as XY 2 . Since there is no Sry gene, these mice are, by default, ovary bearing (gonadal females). The FCG model permits comparisons between XX and XY 2 mice that differ in sex chromosome complement while sharing a common gonadal type (both females throughout development). When Sry is inserted at an autosomal location, it results in XXSry and XY 2 Sry, again differing in sex chromosome complement while sharing a common gonadal type (both male throughout development).
Sex Chromosome Effects in the Immune System of the MS Model EAE
To ascertain whether sex chromosomes could have direct effects on the immune system in the MS model EAE, FCG mice were back-crossed onto the SJL background, a genetic background known to exhibit a greater female susceptibility (Voskuhl, 1996) . Adoptive transfer of autoantigen-stimulated XX immune cells, compared with XY 2 immune cells, into wild-type females led to worse clinical disease and neuropathology, along with decreased Th2 anti-inflammatory cytokines such as interleukin (IL)-10 and IL-13 (Smith-Bouvier et al., 2008) . These studies demonstrated a role for sex chromosomes in the induction of the immune response in adoptive EAE, with the XX complement, as compared with XY 2 , more proinflammatory. A proinflammatory effect of XX compared with XY 2 was also shown in experimental (Smith-Bouvier et al., 2008) and spontaneous (Sasidhar et al., 2012) lupus models.
Sex Chromosome Effects in the CNS of the MS Model EAE
An effect of sex chromosomes in the CNS response to injury during chronic EAE in C57BL/6 mice has been shown (Du et al., 2014) . A challenge in MS models entails discerning whether effects of a treatment on neurodegeneration are merely a consequence of effects on the immune system. Therefore, bone marrow chimeras are widely used to study compartmental effects in vivo in EAE. This entails irradiating mice to abolish their immune system, followed by reconstitution of their immune system using bone marrow from a donor mouse. Sex differences in neurodegeneration in EAE can be discerned if disease is induced in bone marrow chimeric mice that have an immune system of the same genetic sex, while having a CNS with a different genetic sex (XX or XY 2 ) (Du et al., 2014) . Specifically, XX vs. XY 2 bone marrow chimeras were reconstituted with a common immune system of one sex chromosome complement. Using this model, EAE mice with XY 2 sex chromosome complement in the CNS, compared with XX, demonstrated worse EAE clinical disease severity with more neuropathology in the spinal cord (axonal and myelin loss), cerebellum (Purkinje cell and myelin loss), and cerebral cortex (synaptic loss) (Du et al., 2014) . This result in EAE was consistent with males compared to females having faster disability accumulation in MS. As an example of the importance of studying sex chromosomes, a candidate X-linked gene, Toll-like receptor 7 (Tlr7), was examined because of its role in mediating neuronal degeneration in cortical neurons (Lehmann et al., 2012) . Tlr7 protein expression in cortical neurons was higher in mice with XY 2 compared with mice with XX CNS (Du et al., 2014) . This was the first demonstration of a direct effect of sex chromosome complement on neurodegeneration in a neurological disease (Du et al., 2014) .
The study of sex differences in neurodegeneration in the model of MS could reveal new targets for a treatment to halt disability progression in MS. This is important because the current MS treatments target relapses, with only a modest effect on disability progression and with no approved treatments for progressive MS. Treatments to halt disability progression in MS may also warrant consideration in other neurodegenerative diseases characterized by a sex difference, including Parkinson disease and amyotrophic lateral sclerosis (ALS). Parkinson disease is clearly male predominant as shown in a metaanalysis, where being male increased risk 1.5-fold (Wooten et al., 2004) . ALS also demonstrates a male predominance of over 1.5-fold and an earlier onset of disease in men (Norris et al., 1993) .
CONCLUSION
There are many factors that influence disease susceptibility and progression. One important factor is being female or male. Only recently has the importance of studying both sexes been appreciated in both basic and clinical research. Advancements in MS research underscore the need for investigating disease in both males and females. Increased susceptibility of females over males, but increased rate of disability progression of males over females, indicate gender effects on disease mechanisms. Therefore, treatments discovered for one sex may behave differently in the other sex. Additionally, by addressing both sexes, potential new treatments involving the sex hormones estriol and testosterone are being pursued in clinical trials. Finally, addressing sex differences can reveal influences of sex chromosome genes on disease. None of these discoveries would have been possible without inclusion of both sexes in research. Examples such as these have prompted a National Institutes of Health (NIH) policy requiring justification for exclusion of one sex in basic research grants (Clayton and Collins, 2014) , with implementation starting in January 2016 (Clayton, 2016) . This new NIH policy is a win-win situation since experts not usually studying sex differences can ascertain whether their observations in one sex are also present in the other sex. If they are found in the other sex, then they will have extended their work to the other half of the population. If they are not found in the other sex, then investigators will have uncovered an interesting sex difference that could potentially lead to novel targets for disease modifiers.
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